12 Health Care Stocks Moving In Wednesday's After-Market Session

BenzingaApr 23 17:05 ET

Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting

Quiver QuantitativeApr 23 16:15 ET

Express News | Candel Therapeutics Announces Oral Presentation of Positive Phase 3 Can-2409 Results in Localized Prostate Cancer at Asco 2025

ReutersApr 23 16:05 ET

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

GlobeNewswireApr 23 16:05 ET

H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsApr 11 14:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

BenzingaApr 11 06:53 ET